Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

Sponsor
Samsung Medical Center
Study ID
NCT01130753
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Erlotinib 150mg per day for 8 weeks

Study Details

This study propose neoadjuvant chemotherapeutic role by erlotinib.

Key Dates

First listed
May 26, 2010
Start date
Jan 31, 2007
Status verified
May 2013
Primary completion
Dec 31, 2010
Completion
Dec 31, 2012

Study Design

Enrollment
43 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Pathologic down-staging [ Time Frame: 36 months ]

Related Studies